Literature DB >> 19318399

Glu298Asp eNOS polymorphism is not associated with SLE.

T Mucenic1, J C T Brenol, M Bredemeier, B Paiva Dos Santos, J A B Chies, O A Monticielo, R M Xavier.   

Abstract

To examine potential associations of the Glu298Asp polymorphism in the coding region of the endothelial nitric oxide synthase (eNOS) gene with susceptibility to and clinical expression of systemic lupus erythematosus (SLE). One hundred thirteen consecutive patients of European ancestry with diagnosis of SLE, satisfying the American College of Rheumatology criteria, from the outpatient clinic of the Serviço de Reumatologia of the Hospital de Clínicas de Porto Alegre, and 206 healthy controls from the same geographic area were genotyped by polymerase chain reaction for the Glu298Asp polymorphism in the coding region of the eNOS gene. Clinical, demographic, and laboratorial data were collected. Clinical manifestations of SLE and related diseases were evaluated for the association with specific genotypes. The allelic and genotypic distribution of the Glu298Asp did not differ significantly between SLE patients and controls. We found no association of the polymorphism with lupus nephritis, antiphospholipid syndrome, cardiovascular disease (CVD), and risk factors to CVD. The presented results in this study do not provide support for a major role of eNOS Glu298Asp neither in the susceptibility for SLE or clinical manifestations, although there was low statistical power for the latter evaluation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19318399     DOI: 10.1177/0961203308100510

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  2 in total

1.  Associations between eNOS polymorphisms and susceptibility to systemic lupus erythematosus: a meta-analysis.

Authors:  Young Ho Lee; Hye-Soon Lee; Sung Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Inflamm Res       Date:  2011-11-22       Impact factor: 4.575

2.  Associations between eNOS polymorphisms and susceptibility to systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis.

Authors:  Y H Lee; S-C Bae
Journal:  Z Rheumatol       Date:  2017-10       Impact factor: 1.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.